tirzepatide nice GPs should support patients for one year after GLP-1 treatment, says Tirzepatide | GoodGirlRx

Researchers documented these milestones in uncovering the vision risks: Summer 2023: Three NAION cases presented at Mass Eye and Ear within a short period, all involving semaglutide users July 2024: Publication of the landmark Harvard study in JAMA Ophthalmology revealing increased NAION risk December 2024: Danish researchers published supporting studies involving over 424,000 patients 2025: Multiple international studies confirmed the association between semaglutide and vision problems The pivotal Harvard study analyzed medical records from 16,827 patients treated between 2017 and 2023, comparing those prescribed semaglutide against patients using other diabetes or weight loss medications

#Healthcare #Pharma #GLP1 #IndiaPharma #Biotech #WeightLoss #DiabetesCare #FutureOfHealthcare #MedTech India's GLP-1 Drug Market Heats Up with Sun Pharma, Zydus, Lupin Indias GLP-1 Drug Race is Heating Up From diabetes care to weight management, GLP-1 therapies are redefining modern medicine and Indian pharma is stepping in at scale

Please consult your healthcare provider before using Benzonatate and Dextromethorphan It is important to seek guidance when combining Benzonatate with dextromethorphan as they are both cough suppressants and using them simultaneously may overly suppress the cough reflex which could hinder the clearing of mucus from the lungs, in situations

Strategic Move: By outbidding Novo, Pfizer gained precedence among US insulin/protein therapeutics